Legal & General Group Plc lifted its holdings in shares of Alkermes PLC (NASDAQ:ALKS) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 668,021 shares of the company’s stock after purchasing an additional 13,277 shares during the period. Legal & General Group Plc owned about 0.43% of Alkermes worth $33,962,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ALKS. Toronto Dominion Bank raised its stake in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after acquiring an additional 212 shares during the period. Quantbot Technologies LP bought a new stake in Alkermes in the 3rd quarter valued at about $126,000. Greenwood Capital Associates LLC raised its stake in Alkermes by 1.1% in the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after acquiring an additional 41 shares during the period. US Bancorp DE raised its stake in Alkermes by 366.4% in the 2nd quarter. US Bancorp DE now owns 3,974 shares of the company’s stock valued at $231,000 after acquiring an additional 3,122 shares during the period. Finally, IFP Advisors Inc raised its stake in Alkermes by 10.9% in the 2nd quarter. IFP Advisors Inc now owns 4,074 shares of the company’s stock valued at $236,000 after acquiring an additional 402 shares during the period. Institutional investors own 99.69% of the company’s stock.
In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the transaction, the chief accounting officer now owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $50.64, for a total value of $75,960.00. The disclosure for this sale can be found here. Insiders have sold 122,930 shares of company stock valued at $6,051,110 in the last three months. 5.34% of the stock is owned by insiders.
Shares of Alkermes PLC (NASDAQ:ALKS) opened at $52.88 on Friday. Alkermes PLC has a 52-week low of $46.42 and a 52-week high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.
Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm had revenue of $217.40 million for the quarter, compared to analysts’ expectations of $231.29 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The company’s revenue was up 20.6% on a year-over-year basis. equities analysts anticipate that Alkermes PLC will post -0.59 earnings per share for the current year.
A number of brokerages recently issued reports on ALKS. Barclays set a $50.00 price objective on Alkermes and gave the company a “hold” rating in a research note on Thursday, October 26th. ValuEngine cut Alkermes from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. J P Morgan Chase & Co set a $78.00 price target on Alkermes and gave the company a “buy” rating in a research report on Friday, October 27th. Citigroup set a $62.00 price target on Alkermes and gave the company a “hold” rating in a research report on Thursday, October 26th. Finally, Jefferies Group set a $69.00 price target on Alkermes and gave the company a “buy” rating in a research report on Friday, August 25th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Alkermes currently has a consensus rating of “Hold” and an average target price of $63.55.
COPYRIGHT VIOLATION WARNING: This report was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/09/alkermes-plc-alks-stake-raised-by-legal-general-group-plc.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.